Clinical characteristics and outcomes of severe Legionella pneumophila pneumonia diagnosed by metagenomic next-generation sequencing in children: a case series of 8 patients
Abstract
Introduction: Severe Legionella pneumophila (LP) pneumonia is exceedingly rare in children, and clinical data remain scarce.
Methods: We retrospectively analyzed the clinical data of 8 children with severe LP pneumonia diagnosed by metagenomic next-generation sequencing (mNGS) at Henan Children's Hospital between January 2020 and January 2026.
Results: The cohort comprised 3 males and 5 females with a median age of 74 days (range, 8 days to 9 years); neonates accounted for 50.0% (4/8), and 75.0% (6/8) had no underlying diseases. Six cases were community-acquired and 2 were hospital-acquired. The predominant manifestations were tachypnea/dyspnea (100.0%) and fever (87.5%); neonates presented with lethargy and poor feeding. Complications included respiratory failure (87.5%), multiple organ dysfunction (62.5%), and septic shock (37.5%). Procalcitonin, interleukin-6, and LDH were elevated in all cases, while ALB was uniformly decreased. Bilateral pulmonary involvement was seen in 87.5% on chest imaging. mNGS detected LP in all 8 cases (100%), whereas conventional sputum and blood cultures failed to identify LP in any case; LP was isolated from a surgical pus specimen in only 1 case. Co-infections were identified in 50.0%. All initial empirical regimens failed to cover LP. After mNGS-guided targeted therapy, the fluoroquinolone-rifampin combination (2 cases) achieved complete recovery, while macrolide-based regimens yielded variable outcomes. Overall, 50.0% were cured or…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 8 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.